Drug Trial Radar · NCT03690986
VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer
Last checked: Nov 19, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
35
Actual
Start
Nov 1, 2018
Primary completion
Apr 9, 2027
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- Emory UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Vaccinex Inc.
- First posted
- Oct 1, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial studies how well anti-semaphorin 4D (SEMA4D) monoclonal antibody VX15/2503 (VX15/2503) with or without ipilimumab and/or nivolumab work in treating patients with stage I-IVA head and neck squamous cell cancer. Monoclonal antibodies, such as VX15/2503, ipilimumab, and nivolumab, may interfere with the ability of tumor cells to grow and spread.
Conditions
- Squamous Cell Carcinoma of the Head and Neck
Interventions
VX15/2503Biological
Given IV
IpilimumabBiological
Given IV
NivolumabBiological
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in immune profile in the tumor microenvironmentTime frame: Baseline up to 4-8 weeks after surgery
- Change in circulating percentage of immune suppressor subsets in peripheral bloodTime frame: Baseline up to 4-8 weeks after surgery
- Phenotypic shifts in T lymphocyte subsets in peripheral bloodTime frame: Baseline up to 4-8 weeks after surgery
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Emory University Hospital Midtown
Atlanta, Georgia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.